Nursing Management Post Infection Of Ebola Virus

1. Henderson, D. A. The looming threat of bioterrorism. Science 1999, 283, 1279-1282.

2. Monto, A. The role of antivirals in the control of influenza. Vaccine 2003, 21, 1796-1800.

3. Bray, M; Roy, C. J. Antiviral prophylaxis of smallpox. J. Antimicrob. Chemother. 2004,54, 1-5.

4. www.niaid.nih.gov/biodefense.

5. Eitzen, E. M. Use of biological weapons. In Textbook of Military Medicine, Office of the Surgeon General, Department of the Army, Washington, DC, 1997, pp. 437-450.

6. Eitzen, E. M.; Takafuji, E. Historical overview of biological warfare. In Textbook of Military Medicine, Office of the Surgeon General, Department of the Army, Washington, DC, 1997, pp. 415-436.

7. Rotz, L.; Khan, A.; Lillibridge, S. R.; Ostroff, S. M.; Hughes, J. M. Public health assessment of potential biological terrorism agents. Emerging Infect. Dis. 2002, 8, 225-229.

8. Henderson, D; Inglesby, T.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Jahrling, P. B.; Hauer, J.; Layton, M; McDade, J.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T.; Russell, P. K.; Tonat, K. Smallpox as a biological weapon: medical and public health management. JAMA 1999, 281, 2127-2137.

9. Jahrling, P. B. Viral hemorrhagic fevers. In Textbook of Military Medicine, Office of the Surgeon General, Department of the Army, Washington, DC, 1997, pp. 591-602.

10. Borio, L.; Inglesby, T.; Peters, C. J.; Schmaljohn, A. L.; Hughes, J. M.; Jahrling, P. B.; Ksiazek, T.; Johnson, K. M.; Meyerhoff, A.; O'Toole, T.; Ascher, M. S.; Bartlett, J.; Breman, J. G.; Eitzen, E. M. Jr.; Hamburg, M.; Hauer, J.; Henderson, D. A.; Johnson, R. T.; Kwik, G.; Layton, M.; Lillibridge, S.; Nabel, G. J.; Osterholm, M. T.; Perl, T. M.; Russell, P.; Tonat, K.; Working Group on Civilian Biodefense. Hemorrhagic fever viruses as biological weapons—medical and public health management. JAMA 2002, 287, 2391-2405.

11. Franz, D.; Jahrling, P. B; McClain, D. J.; Hoover, D. L.; Byrne, W. R.; Pavlin, J. A.; Christopher, G. W.; Cieslak, T. J.; Friedlander, A. M.; Eitzen, E. M. Jr. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997, 278, 399-411.

12. Smith, J.; Davis, K. Viral encephalitides. In Textbook of Military Medicine, Office of the Surgeon General, Department of the Army, Washington, DC, 1997, pp. 561-589.

13. Alibek, J.; Handelman, S. Biohazard. Random House, New York, 1999.

14. Bray, M.; Buller, R. M. L. Looking back at smallpox. Clin. Infect. Dis. 2004, 38, 882-890.

15. Basler, C. F.; Wang, X.; Muhlberger, E.; Volchkov, V.; Paragas, J.; Klenk, H. D.; Garcia-Sastre, A.; Palese, P. The Ebola virus VP35 protein functions as a type IIFN antagonist. Proc. Natl. Acad. Sci. USA 2000, 97, 12289-12294.

16. Basler, C. F.; Mikulasova, A.; Martinez-Sobrido, L.; Paragas, J.; Muhlberger, E.; Bray, M.; Klenk, H. D.; Palese, P.; Garcia-Sastre, A. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 2003, 77, 7945-7956.

17. Bray, M.; Mahanty, S. Ebola hemorrhagic fever and septic shock. J. Infect. Dis. 2003,188, 1613-1617.

18. Geisbert, T. W.; Hensley, L. E.; Larsen, T.; Young, H. A.; Reed, D. S.; Geisbert, J. B.; Scott, D. P.; Kagan, E.; Jahrling, P. B.; Davis, K. J. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques. Am. J. Pathol. 2003, 163, 2347-2370.

19. Mahanty, S.; Bray, M. Pathogenesis of filoviral hemorrhagic fevers. Lancet Infect. Dis. 2004, 4, 487-498.

20. Geisbert, T. W.; Young, H. A.; Jahrling, P. B.; Davis, K. J.; Kagan. E.; Hensley, E. Mechanism underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages. J. Infect. Dis. 2003, 188, 1618-1629.

21. Van Dissel, J. T.; van Langevelde, P.; Westendorp, R. G.; Kwappenberg, K.; Frolich, M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998, 351, 950-953.

22. Hill, A. V. The genomics and genetics of human infectious disease susceptibility. Annu. Rev. Genomics Hum. Genet. 2001, 2, 373-400.

23. Westendorp, R. G.; Langermans, J. A.; Huizinga, T. W.; Verweij, C. L.; Sturk, A. Genetic influence on cytokine production in meningococcal disease. Lancet 1997, 349, 1912-1917.

24. Baize, S.; Leroy, E. M; Georges, A. J.; Georges-Courbot, M. C.; Capron, M.; Bedjabaga, I.; Lansoud-Soukate, J.; Mavoungou, E. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 2002, 128, 163-168.

25. Dowell, S. F.; Mukunu, R.; Ksiazek, T. G.; Khan, A. S.; Rollin, P. E.; Peters, C. J. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit J. Infect. Dis. 1999, 179 Suppl 1, S87-91.

26. Bray, M. Filoviridae. In Clinical Virology, 2nd Ed., Richman, D. R.; Whitley, R. J.; Hayden, F. G. (eds.), ASM Press, Washington, DC, 2002, pp. 875-890.

27. Bray, M. Defense against filoviruses used as biological weapons. Antiviral Res. 2003, 57, 53-60.

28. Anonymous. Infection control for viral hemorrhagic fevers in the African health care setting. Centers for Disease Control and Prevention, Atlanta, 1998.

29. Baker, R. O.; Bray, M.; Huggins, J. W. Potential antiviral therapeutics for smallpox and other orthopoxvirus infections. Antiviral Res. 2003, 57, 13-23.

30. Neyts, J.; De Clercq, E. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antiviral Res. 2003, 57, 25-33.

31. Bray, M.; Kefauver, D.; Martinez, M.; West, M.; Roy, C. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res. 2002, 54, 129-142.

32. Roy, C.; Baker, R.; Washburn, K.; Bray, M. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge. Antimicrob. Agents Chemother. 2003, 47, 2933-2937.

33. Kern, E. R.; Hartline, C.; Harden, E.; Keith, K.; Rodriguez, N.; Beadle, J. R.; Hostetler, K. Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 2002, 46, 991-995.

34. Ciesla, S.; Trahan, J.; Wan, W. B.; Beadle, J. R.; Aldern, K. A.; Painter, G. R.; Hostetler, K. Y. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 2003, 59,163-171.

35. Bray. M; Martinez, M.; Smee, D.; Kefauver, D.; Thompson, E.; Huggins, J. W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus infection. J. Infect. Dis. 2000, 181, 10-19.

36. Andrei, G.; De Clercq, E. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993, 22, 45-75.

37. Bray, M.; Paragas, J. Experimental therapy of filovirus infections. Antiviral Res. 2002, 54, 1-17.

38. Geisbert, T. W.; Hensley, L. E.; Jahrling, P. B.; Larsen, T.; Geisbert, J. B.; Paragas, J.; Young, H. A.; Fredeking, T. M.; Rote, W. E.; Vlasuk, G. P. Treatment of Ebola virus infection with a recombinant inhibitor of factor Vila/tissue factor: a study in rhesus monkeys. Lancet 2003, 362, 1953-1958.

Swine Influenza

Swine Influenza

SWINE INFLUENZA frightening you? CONCERNED about the health implications? Coughs and Sneezes Spread Diseases! Stop The Swine Flu from Spreading. Follow the advice to keep your family and friends safe from this virus and not become another victim. These simple cost free guidelines will help you to protect yourself from the swine flu.

Get My Free Ebook


Post a comment